MedTrace Logo

A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia.

NCT07011485 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-06-08

No results posted yet for this study

Summary

This study will evaluate the safety and efficacy of PDFE-2304 compared with Minoxidil 5% in men with androgenic alopecia (AGA).

Conditions

  • Alopecia, Androgenetic
  • Baldness
  • Androgenetic Alopecia (AGA)

Interventions

DRUG

Minoxidil 5% Topical Solution

Approximately one mL dose applied onto a pre-specified scalp area twice daily for 16 weeks.

DRUG

PDFE-2304 Topical Solution

Approximately one mL dose applied onto a pre-specified scalp area twice daily for 16 weeks.

Sponsors & Collaborators

  • PDFE Pharma Innovations FZCO

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-14
Primary Completion
2025-08-14
Completion
2025-09-17

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07011485 on ClinicalTrials.gov